A pooled analysis linked hormone therapy with more frequent and longer migraines after menopause. Read the findings in their clinical context.
On October 15, 2026, The Menopause Society reported that a pooled analysis linked hormone therapy use with more frequent and longer migraine episodes in postmenopausal women. The research was scheduled for presentation at the Society’s 2026 Annual Meeting in San Diego.
The finding enters a care discussion in which hormone therapy already has a recognised role. Stephanie Faubion, medical director for The Menopause Society, said hormone therapy remains the most effective treatment for bothersome vasomotor symptoms. She also said many women with migraine can use it safely.
The American College of Obstetricians and Gynecologists (ACOG) frames starting hormone therapy as a shared decision based on symptoms and personal health circumstances. Treatment goals and priorities are part of that assessment. That approach makes room for both the reason treatment is being used and concerns that arise during care.
The new analysis adds information about migraine patterns to that conversation. It does not replace the broader framework with a simple rule about whether women with migraine should use hormone therapy. For background, Refemina’s guide to the questions behind a hormone therapy decision provides a wider starting point.
According to The Menopause Society, the systematic review and meta-analysis examined hormone therapy, or HT, and migraine outcomes after menopause. It considered several separate measures rather than treating migraine burden as a single result. The analysis did not restrict study inclusion by the route through which HT was administered.
The Society reported these findings:
These outcomes should remain separate when interpreting the headline. Frequency describes how often attacks occur. Duration describes how long episodes last. Neither is the same measure as a severity score or the number of analgesics used each month.
A fair account therefore needs to retain both parts of the result: the association involving frequency and duration, and the absence of statistically significant differences in the other reported measures. Reducing the analysis to “HT worsens migraine” loses that distinction. Reducing it to “pain scores did not change” leaves out the findings that prompted the announcement.
Lead author Flavia Fairbanks Ruano of the University of Miami Miller School of Medicine said migraines can affect quality of life during the menopause transition. She called for more research to guide individualized decisions. That focus matters because the clinical question is not simply whether a result reaches statistical significance, but how it belongs in a person’s wider care.
The analysis reports an association, not proof that HT caused the differences. Faubion identified a possible source of bias: women with migraine may be more likely to seek treatment for menopause symptoms. Underlying differences between HT users and nonusers could therefore help explain the finding rather than an effect of HT itself.
The 18.94% figure is not the proportion of migraines caused by hormone therapy. The release gives no comparison-group incidence rate. It also provides no numerical effect sizes or confidence intervals for the reported differences. The public summary therefore does not show how large the association was or provide the detail needed to assess its precision.
Other missing details affect how widely the findings can be applied. The summary does not provide the individual study designs or participant characteristics. It also omits treatment formulations and doses, so inclusion across administration routes does not establish that every formulation has the same relationship with migraine. The study concerns postmenopausal women and provides no separate perimenopause analysis.
Finally, no statistically significant difference in severity or analgesic use does not mean that every individual’s pain or medication needs stayed unchanged. Those are pooled group-level results. The Society says further clinical trials are needed to clarify the relationship and guide treatment.
The practical value of this finding is a more focused discussion with the clinician managing menopause care. For someone using HT who notices a change in migraine patterns, recording when attacks occur may help make that discussion more specific. This is a practical suggestion, not a procedure tested in the pooled analysis.
A record can distinguish attacks that happen more often from episodes that last longer. It can also keep the description of severity separate from the description of frequency. The aim is to bring a clearer account of the change to qualified care, rather than trying to diagnose its cause from a headline.
Questions that fit the evidence and ACOG’s shared decision-making approach include:
There is no need to reduce this conversation to defending hormone therapy or rejecting it. Symptom relief and a changing migraine pattern can be discussed together. Recognising one does not require dismissing the other, and the purpose of the appointment is to interpret both within the same health picture.
For a broader overview, Refemina’s guide to placing different menopause care approaches side by side offers context for that discussion. The relevant question is how care fits the individual’s symptoms and priorities, not which option wins a general argument online.
ACOG says decisions about starting HT should account for symptoms and age alongside medical history. Its recommended assessment includes baseline cardiovascular disease risk and breast cancer risk. Venous thromboembolism risk is also part of that discussion, together with the person’s treatment goals and priorities.
Migraine findings belong within that assessment rather than replacing it. The new analysis addresses particular migraine outcomes, while the treatment decision involves the reason HT is being used and the individual’s wider circumstances. Keeping those questions together is more useful than treating a single pooled finding as a complete answer about treatment suitability.
The same individualized approach applies to continuing or discontinuing treatment. ACOG says decisions about whether and when to stop HT should be discussed with a clinician as benefits and risk factors are reassessed. This result alone is not a reason to start, stop or alter hormone therapy.
That leaves room for a clear response without a blanket recommendation: bring a meaningful change in migraine patterns to the treating clinician and discuss it alongside treatment benefits and health history. A concern deserves attention without automatically becoming a reason for another medicine or a different hormone regimen.
The useful clinical direction is a more specific migraine discussion within individualized menopause care, supported by further trials rather than a blanket change in hormone therapy practice.
Day-to-day questions about migraine and hormone therapy sit with women and their treating clinicians; Refemina’s role is to make the research easier to understand. When health coverage turns a complex decision into a treatment pitch, its research-led reporting helps readers distinguish evidence from claims without presenting hormones or supplements as a universal answer.
Follow Refemina for research-led insights on menopause, strength, metabolism, nutrition, skin, intimacy and confidence through midlife. New articles turn complex topics into clear, useful context.
Keep learning about the changes that shape energy, strength, confidence and wellbeing through midlife.
Explore Resources